



February 15, 2024

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

We are pleased to enclose a Press Release as regards, launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the U.S. FDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl: a/a.**

## Lupin Launches Ganirelix Acetate Injection in the United States

*Ganirelix is Lupin's first peptide-based injectable, strengthening the Company's commitment to innovative healthcare solutions*

**Mumbai, Baltimore, February 15, 2024:** Global pharma major Lupin Limited (Lupin) today announced the launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

Ganirelix Acetate Injection had estimated annual sales of USD 87 million in the U.S. (IQVIA MAT December 2023).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

**For further information or queries please contact –**

**Heena Dhedhi**

Deputy General Manager – Corporate Communications

Email: [heenadhedhi@lupin.com](mailto:heenadhedhi@lupin.com)